Allows licensed pharmacists to initiate treatment for COVID-19, influenza, and pharyngitis caused by Group A streptococcal infection under certain.

This bill amends the education law to allow licensed pharmacists to initiate treatment for COVID-19, influenza, and pharyngitis resulting from a Group A streptococcal infection. The treatment must follow a statewide protocol developed by the Department of Health, which includes patient safety, record-keeping, and continuity of care. The bill also requires the Department of Health to maintain a list of primary care providers, including those who serve Medicaid, low-income, and uninsured patients. The provisions of this bill are set to expire on April 1, 2028.

Allows licensed pharmacists to initiate treatment for COVID-19, influenza, and pharyngitis caused by Group A streptococcal infection under certain.

This bill amends the education law to allow licensed pharmacists to initiate treatment for COVID-19, influenza, and pharyngitis resulting from a Group A streptococcal infection. The treatment must follow a statewide protocol developed by the Department of Health, which includes patient safety, record-keeping, and continuity of care. The bill also requires the Department of Health to maintain a list of primary care providers, including those who serve Medicaid, low-income, and uninsured patients. The provisions of this bill are set to expire on April 1, 2028.